The Role of Endocan in Cardiometabolic Disorders
Discovered two decades ago, endocan still represents an intriguing biomarker related to inflammation. Endocan is a soluble dermatan sulphate proteoglycan secreted by endothelial cells. Its expression is observed in tissues related to the enhanced proliferation, especially hepatocytes, lungs, kidneys...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/13/5/640 |
| _version_ | 1797599131183611904 |
|---|---|
| author | Aleksandra Klisic Dimitrios Patoulias |
| author_facet | Aleksandra Klisic Dimitrios Patoulias |
| author_sort | Aleksandra Klisic |
| collection | DOAJ |
| description | Discovered two decades ago, endocan still represents an intriguing biomarker related to inflammation. Endocan is a soluble dermatan sulphate proteoglycan secreted by endothelial cells. Its expression is observed in tissues related to the enhanced proliferation, especially hepatocytes, lungs, kidneys, etc. Endocan has been investigated in many cardiometabolic disorders that are tightly connected with inflammation, such as type 2 diabetes mellitus, hypertension, atherosclerotic cardiovascular disease, kidney disease, obesity, polycystic ovary syndrome, metabolic syndrome, non-alcoholic fatty liver disease, etc. In this narrative, comprehensive review of the currently available literature, special attention will be paid to the role of endocan in the broad spectrum of cardiometabolic disorders. Since endocan has emerged as a novel endothelial dysfunction marker, the discovery of potential therapeutic strategies for patients with certain cardiometabolic risk factors would be of great importance to delay or even prevent the onset and progression of related complications, mainly cardiovascular. |
| first_indexed | 2024-03-11T03:30:23Z |
| format | Article |
| id | doaj.art-6e73e9a357504b27a78dc17d6d55f73b |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-11T03:30:23Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-6e73e9a357504b27a78dc17d6d55f73b2023-11-18T02:25:43ZengMDPI AGMetabolites2218-19892023-05-0113564010.3390/metabo13050640The Role of Endocan in Cardiometabolic DisordersAleksandra Klisic0Dimitrios Patoulias1Primary Health Care Center, Faculty of Medicine, University of Montenegro, 81000 Podgorica, MontenegroOutpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokration”, 54642 Thessaloniki, GreeceDiscovered two decades ago, endocan still represents an intriguing biomarker related to inflammation. Endocan is a soluble dermatan sulphate proteoglycan secreted by endothelial cells. Its expression is observed in tissues related to the enhanced proliferation, especially hepatocytes, lungs, kidneys, etc. Endocan has been investigated in many cardiometabolic disorders that are tightly connected with inflammation, such as type 2 diabetes mellitus, hypertension, atherosclerotic cardiovascular disease, kidney disease, obesity, polycystic ovary syndrome, metabolic syndrome, non-alcoholic fatty liver disease, etc. In this narrative, comprehensive review of the currently available literature, special attention will be paid to the role of endocan in the broad spectrum of cardiometabolic disorders. Since endocan has emerged as a novel endothelial dysfunction marker, the discovery of potential therapeutic strategies for patients with certain cardiometabolic risk factors would be of great importance to delay or even prevent the onset and progression of related complications, mainly cardiovascular.https://www.mdpi.com/2218-1989/13/5/640atherosclerosisendocanendothelial dysfunctioninflammation |
| spellingShingle | Aleksandra Klisic Dimitrios Patoulias The Role of Endocan in Cardiometabolic Disorders Metabolites atherosclerosis endocan endothelial dysfunction inflammation |
| title | The Role of Endocan in Cardiometabolic Disorders |
| title_full | The Role of Endocan in Cardiometabolic Disorders |
| title_fullStr | The Role of Endocan in Cardiometabolic Disorders |
| title_full_unstemmed | The Role of Endocan in Cardiometabolic Disorders |
| title_short | The Role of Endocan in Cardiometabolic Disorders |
| title_sort | role of endocan in cardiometabolic disorders |
| topic | atherosclerosis endocan endothelial dysfunction inflammation |
| url | https://www.mdpi.com/2218-1989/13/5/640 |
| work_keys_str_mv | AT aleksandraklisic theroleofendocanincardiometabolicdisorders AT dimitriospatoulias theroleofendocanincardiometabolicdisorders AT aleksandraklisic roleofendocanincardiometabolicdisorders AT dimitriospatoulias roleofendocanincardiometabolicdisorders |